http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
어린이 김치 표준화에 대한 연구(1) : 어린이 김치의 담금법 개발 Development of the Preparation of Kimchi for the Children
송영옥,전영수,권명자,빈성미,김은희,문정원,김명 부산대학교 가정대학 1995 家政大學硏究報告 Vol.21 No.-
The purpose of this study is reporting the results of first trial for the standardization of children's kimchi in terms of brining standardization, development for the recipe ad pannel test for the children's kimchi. In order to develop the standard recipe for children's kimchi, our research team have visited kimchi factories, temples and houses located in Pusan and Kyung-Sang Nam Do province. Three kinds of chinese cabbage kimchi (hamyang, haeundae, and jinrae kimchi named by region where we collected) which got the top three highest score in panel testing was selected. The original recipes of these kimchi were sightly modified to prepared the kimchi at laboratory. Among three of them, hamyang kimchi which contained dried anchovy power was selected as a model kimchi for development of the children's kimchi recipe. We find out that the optimal salt concentration of brined cabbage and kimchi for the children's kimchi (sliced style kimchi, approximately 2.5X3cm a piece) that showed the hightest pennel score were approximately 1.5% and 2.0%, respectively. The salt concentration of brined cabbage became 1.5, 1.43, and 1.60% after 60 min at 10% brining solution, 45 min at 12% and 30 min at 15%, respectively. The developed recipe used for the children's kimchi at our team is as follows. The major ingredients used for the preparation of kimchi is brined sliced chinese cabbage (salt concentration is 1.5%) 1kg galic 11g, ginger 5.0g, red pepper powder 20.0g, fermented anchovy juice 25.0g, fermented shrimp juice 5.0g dried anchovy and sea weed extracts 30.0g, anchovy power 2.4g glutinious rice gel 40.0g, starch syrup, 10.0g, and apple juice 22.5g. The total acceptability test of developed children's kimchi (test kimchi) was carried out with 84 of 6th grade student during lunch time at elementary school in Pusan where has a school lunch program. Sixty nine percent of student answered test kimchi is very good, 25% of them said it is fair, and only 6% of students answered they didn't like test kimchil. However, for the kimchi supplied from school at lunch, 52% students answered the kimchi is good, 26% of them said it is fair, and 22% of them said they don't like school supplied kimchi. This result tells us that the test kimchi is better than school supplied kimchi and the test kimchi can be developed further as a children's kimchi.
張明洙,宋浚泰 全北大學校 附設 都市및環境硏究所 1990 都市 및 環境硏究 Vol.5 No.-
The purpose of this study is to, through the research of the history of Chonju, find out the object of restoration among historic remains damaged artificially, preserve the characteristics of the areas in which historic remains existing right now are cellectively distributed and to re-organize their historic environment coupled with cultural individuality and peculiarity. The results of the study are summarized as follows; First, the East gate, the West gate, and the North gate except for the presently existing the South gate should be restored, and Sun Hwa Dang which was the center of Kwan-A in the old castle (old Chonju city) and other accessory buildings restored. Second, in order to solve these problems mentioned above, I propose that area of human activity, one of the elements for urban landscape, be organized.
( Myeong Jun Song ),( Jeong Won Jang ),( Si Hyun Bae ),( Jong Young Choi ),( Seung Kew Yoon ),( Hee Yeon Kim ),( Chang Wook Kim ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Chan Ran You ),( San 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: We aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) therapy in naïve chronic hepatitis B (CHB) patients for 144 weeks in Korean real life practice. Methods: 579 naïve CHB patients at 12 medical centers were enrolled from Sep, 2015 to Jan, 2016 by retrospective and prospective design (NCT02533544). We compared the virological responses (HBV DNA< 116 copies) and renal safety of treatment naive patients. Results: In this cohort, 465 (80.3%), 298 (51.4%) and 157 (27.1%) CHB patients completed 48, 96, and 144 weeks, respectively. Overall complete virological response (CVR) showed 59.5%, 78.1%, and 79.6% of patients at week 48, 96, and 144 respectively. In HBeAg positive CHB, CVR at week 48, 96 and 144 showed 49.0%, 71.7% and 78.4%, respectively. HBeAg loss and seroconversion rate at week 46, 96, and 144 showed 17.8%, 22.7%, 36.3%, and 7.8%, 9.2%, 14.7%, respectively. In HBeAg negative CHB, CVR at week 48, 96 and 144 showed 75.0%, 87.5% and 81.3%, respectively. Overall ALT normalization showed 76.2%, 81.1%, and 84.11% of patients at week 48, 96, and 144 respectively. In multivariate analysis, HBeAg positive showed independent factors of CVR at week 46 and 96, although baseline HBV DNA was independent factor of CVR at week 48. However, at week 144, there was no significant factor of CVR including viral factors, BMI, and comorbidities. In renal safety, 2(0.9%) CHB patients showed elevated creatinine ( >0.5mg/dL). In analysis for change of eGFR, older age (≥65) showed significant reduction at week 48 and 96 (P=0.00415 and 0.0412, respectively). Comorbidities (diabetes or hypertension) also significantly showed reduction at week 48 (P=0.0098). Conclusions: TDF therapy demonstrated sustained viral suppression and a favorable safety throughout 3 years. However, close monitoring of eGFR should be mandatory when treating CHB patients receiving TDF, particularly those with older age or comorbidities.
( Myeong Jun Song ),( Jung Hyun Kwon ),( Soon Woo Nam ),( Tae Hee Lee ),( Young Woo Kang ),( Ji Woong Jang ),( Seok Hyun Kim ),( Byung Seok Lee5 ),( Sea Hwan Lee ),( Hong Soo Kim ),( Ji Hoon Kim ),( S 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: We aimed to evaluate the efficacy and safety of Daclatasvir (DAV) and Asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) and chronic renal failure (CRF). Methods: 22 chronic hemodialysis patients with HCV infection at 12 medical centers have prospectively enrolled from Feb, 2016 to Feb, 2017 (NCT02580474). Of those, 9 patients who were followed 12 weeks after treatment ended were included. We evaluated the virological responses at each week 4, 12, 24 and the 12-week sustained virologic response (SVR12). The tolerability and safety of patients were also evaluated. Results: Of these 20 patients, there had no resistance-associated variant of NS5A (NS5A RAVs) and 2 patients showed indeterminate NS5A RAVs. 12 patients (54.5%) completed the 24 weeks treatment of DAV and ASV. 6 patients (27.2%) have continued, but 4 patients discontinued study prior to 12 weeks. Overall, all patients (n=9) achieved SVR12. Virologic response at week 4, 12 and 24 showed 94.4% (17/18), 93.3% (14/15), and 100% (12/12) respectively. DCV and ASV were well tolerated among the majority of patients and discontinuation of the treatment due to adverse events (hypertension, bradycardia, leukemia) was occurred in 3 patients. In two patients with indeterminate NS5A RAVs, one achieved SVR12 but the other showed viral breakthrough and discontinued treatment. Conclusions: In this study, DAV and ASV combination therapy for chronic hemodialysis patients with HCV infection achieved high sustained virological response with few adverse events. Close monitoring of safety and tolerability may be necessary when treating chronic hepatitis C patients with CRF receiving DCV and ASV.
( Myeong Jun Song ),( Si Hyun Bae ),( June Sung Lee ),( Sung Won Lee ),( Do Seon Song ),( Chan Ran You ),( Jong Young Choi ),( Seung Kew Yoon ) 대한내과학회 2016 The Korean Journal of Internal Medicine Vol.31 No.2
Background/Aims: We compared the recurrence of hepatocellular carcinoma (HCC) and the survival of patients who received radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated with TACE or RFA alone. Methods: This study included 201 patients with HCC, who were consecutively enrolled at Seoul St. Mary’s Hospital between December 2004 and February 2010. Inclusion criteria were a single HCC≤5.0 cm or up to three HCCs≤3.0 cm. We used a propensity score model to compare HCC patients (n = 87) who received RFA after TACE (TACE + RFA) with those who received TACE (n = 71) or RFA alone (n = 43). Results: The median follow-up period was 33.3 months (range, 6.8 to 80.9). The TACE + RFA group showed significantly lower local recurrence than the RFA or TACE groups (hazard ratio [HR], 0.309; 95% confidence interval [CI], 0.130 to 0.736; p = 0.008; and HR, 0.352; 95% CI, 0.158 to 0.787; p = 0.011, respectively). The overall survival was significantly better in the TACE + RFA group compared to the RFA group (HR, 0.422; 95% CI, 0.185 to 0.964; p = 0.041). However, the survival benefit was not different between the TACE + RFA and TACE groups (p = 0.124). Subgroup analysis showed that among patients with a tumor size < 3 cm, the TACE + RFA group had significantly better long-term survival than those in the TACE or RFA groups (p = 0.017, p = 0.004, respectively). Conclusions: TACE + RFA combination treatment showed favorable local recurrence and better overall survival rates in early-stage HCC patients. Patients with tumors < 3 cm are likely to benefit more from TACE + RFA combination treatment. Additional studies are needed for the selection of suitable HCC patients for TACE + RFA treatment.
Song, Myeong Jun,Bae, Si Hyun,Yoo, Ie Ryung,Park, Chung-Hwa,Jang, Jeong Won,Chun, Ho Jong,Choi, Byung Gil,Lee, Hae Giu,Choi, Jong Young,Yoon, Seung Kew WJG Press 2012 WORLD JOURNAL OF GASTROENTEROLOGY Vol.18 No.25
<P>To investigate the correlation of ¹???F-fluorodeoxyglucose (¹???F-FDG) positron emission tomography (PET) with clinical features and the prediction of treatment response.</P>
Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
Song, Myeong Jun,Song, Do Seon,Kim, Hee Yeon,Yoo, Sun Hong,Bae, Si Hyun,Choi, Jong Young,Yoon, Seung Kew,Paik, Yong-Han,Lee, June Sung,Lee, Hyun Woong,Kim, Hyung Joon WJG Press 2012 WORLD JOURNAL OF GASTROENTEROLOGY Vol.18 No.43
<P>To evaluate the durability in hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients who discontinued antiviral treatment.</P>